Hypertrophic Obstructive Cardiomyopathy Clinical Trial
— SAFECAREOfficial title:
Safety and Efficacy of Stereotactic Body Radiotherapy in the Treatment of Hypertrophic Obstructive Cardiomyopathy: A Multicenter, Randomized, Single-blind, Controlled Study
This study is designed to rigorously evaluate the safety and effectiveness of Stereotactic Body Radiotherapy (SBRT) as an innovative, non-invasive treatment for Hypertrophic Obstructive Cardiomyopathy (HOCM). HOCM, a prevalent cardiac condition, is primarily characterized by asymmetric septal hypertrophy, which results in the obstruction of the left ventricular outflow tract. This obstruction significantly compromises patient quality of life and is associated with severe risks, including arrhythmias and sudden cardiac death. While current treatments like medications, surgical septal myectomy, and percutaneous transluminal septal myocardial ablation (PTSMA) have proven to be effective, they are not without limitations. SBRT, a recent development in non-invasive cardiac radioablation, has shown encouraging results in early-stage studies, suggesting its potential as a safe and feasible option for HOCM treatment. In this study, participants will be randomly assigned to either the SBRT treatment group or a control group receiving a sham procedure. The primary objective is to measure the change in the left ventricular outflow tract pressure gradient under provoked conditions, using cardiac ultrasound at a 6-month follow-up. This will provide a clear assessment of the direct impact of SBRT on the primary physiological complication of HOCM. The study also sets forth several secondary objectives to provide a holistic view of the treatment's impact. These include evaluating changes in NYHA functional classification and KCCQ scores to assess improvements in symptom severity and quality of life, respectively. Additionally, we will monitor physical capacity through the 6-minute walk test, and biomarkers like NT-proBNP and cTNT for cardiac stress and damage. The effect of SBRT on QRS duration will be analyzed to understand its impact on cardiac electrical activity. The incidence of major adverse cardiac events (MACEs) within 6 months post-treatment will be recorded to evaluate safety, and the need for invasive septal reduction therapy post-treatment will be assessed to gauge long-term efficacy. This study aims to provide a comprehensive understanding of the potential of SBRT as a treatment alternative for HOCM. By comparing its outcomes with those of traditional therapies, the study seeks to establish SBRT's role in symptom alleviation, quality of life enhancement, and risk reduction in HOCM management.
Status | Recruiting |
Enrollment | 36 |
Est. completion date | June 15, 2025 |
Est. primary completion date | December 15, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults aged 18 years or older. - Confirmed diagnosis of Hypertrophic Obstructive Cardiomyopathy (HOCM) with a left ventricular outflow tract resting pressure gradient of 50mmHg or greater, as evidenced by cardiac ultrasound or Cardiac MRI. - Willingness and consent to undergo non-invasive cardiac radioablation technology for the treatment of HOCM. - Provision of informed consent, indicating voluntary participation in the study. - Capability to read, understand, and communicate in Chinese for study-related procedures and consent. Exclusion Criteria: - Participation in any interventional clinical trial within 30 days prior to enrollment in this study, excluding participation in non-interventional and diagnostic reagent studies. - Previous receipt of any invasive treatment options for HOCM. - Advanced heart failure characterized by NYHA functional class IV. - A left Ventricular Ejection Fraction (LVEF) of less than 30%. - Concurrent severe illnesses that are life-limiting with an expected lifespan of less than one year. - Planned or requirement for any form of surgical intervention. - Pregnancy or currently breastfeeding. - Involvement in the execution or implementation of this study, including study staff and their immediate family members. |
Country | Name | City | State |
---|---|---|---|
China | Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University | Changsha | Hunan |
China | The Second Xiangya Hospital of Central South University | Changsha | Hunan |
China | The First Affiliated Hospital of University of South China | Hengyang | Hunan |
China | Xiangtan Central Hospital | Xiangtan | Hunan |
Lead Sponsor | Collaborator |
---|---|
Second Xiangya Hospital of Central South University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Left Ventricular Outflow Tract Pressure Gradient under Provoked Conditions | This primary outcome measure evaluates the effectiveness of non-invasive radiotherapy (SBRT) in altering the left ventricular outflow tract pressure gradient under provoked conditions in patients with Hypertrophic Obstructive Cardiomyopathy (HOCM). The measurement is determined using cardiac ultrasound, assessing the extent to which SBRT can alleviate the obstruction in the heart's outflow tract, a key indicator of therapeutic success in HOCM treatment. | 6 months post-treatment | |
Secondary | Change in Left Ventricular Outflow Tract Pressure Gradient under Resting Conditions | This measure assesses the change in the left ventricular outflow tract pressure gradient under resting conditions in HOCM patients, using cardiac ultrasound at a 6-month follow-up. It aims to evaluate the impact of non-invasive SBRT treatment on cardiac function during periods of rest. | 6 months post-treatment | |
Secondary | Impact on NYHA Functional Classification | This outcome evaluates the effect of SBRT on the NYHA functional classification of patients, indicating changes in symptomatic heart failure and overall cardiac performance post-treatment. | 6 months post-treatment | |
Secondary | Changes in Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores | This measure evaluates the effect of treatment on patient quality of life and symptomatic relief. It is quantified using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a comprehensive scale that measures heart failure symptoms and their influence on daily activities. The KCCQ scale ranges from 0 to 100, where higher scores indicate better health status and lower scores signify worse outcomes. This scale effectively captures the patient's experience and the impact of heart failure on their quality of life. | 6 months post-treatment | |
Secondary | Performance in the 6-Minute Walk Test | This outcome evaluates the physical capacity of patients post-treatment, measured through the 6-minute walk test, a standard test of aerobic capacity and endurance. | 6 months post-treatment | |
Secondary | Concentration Changes of NT-proBNP and cTNT Post-SBRT Treatment | This measure monitors the levels of NT-proBNP and cTNT, biomarkers of cardiac stress and damage, post-SBRT treatment, providing insights into the physiological changes within the heart. | 6 months post-treatment | |
Secondary | Impact on QRS Duration | This outcome analyzes the effect of SBRT on QRS duration, assessed through electrocardiogram (ECG), to understand any changes in cardiac electrical activity post-treatment. | 6 months post-treatment | |
Secondary | Incidence of Major Adverse Cardiac Events (MACEs) | This measure tracks the occurrence of major adverse cardiac events within 6 months post-treatment, offering crucial data on the safety profile of SBRT in treating HOCM. | 6 months post-treatment | |
Secondary | Monitoring of Serious Adverse Events (SAEs) | This measure involves meticulous monitoring of any serious adverse events during and after treatment, ensuring a comprehensive safety assessment of SBRT as a therapeutic approach. | Up to 6 months post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05073094 -
Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy
|
Phase 4 | |
Completed |
NCT05850026 -
Mitral Regurgitation in Hypertrophic Obstructive Cardiomyopathy: Fix it in a Simple, Effective and Durable Way!
|
||
Completed |
NCT04777188 -
Speckle Tracking Echocardiography Analysis of Left Ventricular Myocardium After Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
Completed |
NCT02054221 -
Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Insufficiency.
|
N/A | |
Withdrawn |
NCT04905173 -
Comparison of Squat-to-Stand Maneuver With Amyl Nitrite, Valsalva, and Exercise Stress Echocardiography in Inducing Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy
|
N/A | |
Completed |
NCT04066777 -
The Effect of TASH in Patients With HOCM
|
N/A | |
Terminated |
NCT02674958 -
Mobilization of Endothelial Progenitor Cells and Aspirin
|
Phase 3 | |
Not yet recruiting |
NCT04329689 -
Hyp Obst Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT05025644 -
Quantitative Assessment of Hypertrophic Obstructive Cardiomyopathy With Intraoperative Three-dimensional Transesophageal Echocardiography Under Provocative Dobutamine Stress Test
|
Phase 4 | |
Recruiting |
NCT05257772 -
Electromechanically Optimised Right Ventricular Pacing In Hypertrophic Cardiomyopathy (EMORI-HCM)
|
N/A | |
Recruiting |
NCT04470102 -
Edge-to-edge Mitral Valve Repair in the Surgical Treatment for Hypertrophic Cardiomyopathy
|
N/A | |
Recruiting |
NCT04355260 -
The Clinical Research of the Safety and Effectiveness Evaluation for Using Echocardiography-guided Liwen RF Radiofrequency Ablation System to Treat Hypertrophic Obstructive Cardiomyopathy
|
N/A | |
Active, not recruiting |
NCT06003478 -
The Safety and Influencing Factors of Liwen Procedure in The Treatment of Hypertrophic Cardiomyopathy
|
||
Recruiting |
NCT05957419 -
Transapical Beating-Heart Septal Myectomy in Patient With Hypertrophic Obstructive Cardiomyopathy: a Multi-Center Study
|
N/A | |
Recruiting |
NCT02492399 -
Comparisonof Extended Myoectomy and Myoectomy by Morrow in Patients With Hypertrophic Obstructive Cardiomyopathy (HOCM)
|
N/A | |
Completed |
NCT04686487 -
SterEotactic AbLative Radiotherapy in PatiEnts With HypertrophiC ObstrucTive Cardiomyopathy
|
N/A | |
Completed |
NCT05671367 -
Association Between Microvascular Resistance and Outcomes in Patients With Obstructive Hypertrophic Cardiomyopathy
|
||
Completed |
NCT05687487 -
Residual or Recurrent Obstruction After Septal Myectomy
|
||
Enrolling by invitation |
NCT05100420 -
Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository
|
||
Not yet recruiting |
NCT04275544 -
Risk Factors of Postoperative Complications in HCM Patients
|